MicroPort品牌怎么样 申请店铺

我要投票 MicroPort在医疗器械行业中的票数:95 更新时间:2025-01-23
MicroPort是哪个国家的品牌?「MicroPort」是上海微创医疗器械(集团)有限公司旗下著名品牌。该品牌发源于上海市,由创始人常董在1998年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
MicroPort怎么样

始于1998年,集医疗器械开发、制造及营销于一体,专注于心血管介入产品/骨科医疗器械等研制的集团公司,以药物支架著称


微创®起源于1998年成立的上海微创医疗器械(集团)有限公司,是一家中国出色的创新型医疗器械集团,总部位于中国上海张江科学城(上海市浦东新区张东路1601号) ,在中国上海、苏州、嘉兴、东莞,美国孟菲斯,法国巴黎近郊,意大利米兰近郊和多米尼加共和国等地均建有主要生产(研发)基地,形成了全球化的研发、生产、营销和服务网络。公司现有员工约5,000名,来自于30多个国家,其中过半数为中国员工。微创®专注于通过持续创新,为医生提供能挽救并重塑患者生命或改善其生活质量的真善美惠医疗解决方案。

微创®已上市产品约300个,覆盖心血管介入及结构性心脏病医疗、心脏节律管理及电生理医疗、骨科植入与修复、大动脉及外周血管介入、神经介入及脑科学、糖尿病及内分泌管理、泌尿及妇女健康、外科手术、医疗机器人与人工智能等十大业务集群。微创®的产品已进入全球逾8,000家医院,覆盖亚太、欧洲和美洲等主要地区。在全球范围内,平均每12秒就有一个微创®的产品被用于救治患者生命或改善其生活品质或用于帮助其催生新的生命。2014年推出的药物靶向洗脱支架系统更是令微创®在冠脉支架领域完成了从追随者和并跑者到全球带领者的跨越。

微创®人的创新动力源于一个属于患者和医生的品牌观,一切经营活动的理念和动机皆源自于患者,为了患者和用之于患者;一切创新的想法皆取之于医生,为了医生,并归之于医生。 “日月不以毫末而不照,雨露不以草草而不滋”,微创®人坚定地信仰人人都有生而平等的医疗权、健康权和追求活得更久的权利,并希冀与社会各界通力合作,为人人享有这种权利而积极创造各种各样的变革性医疗手段。微创®的远景(“以人为本,在以微创伤为代表的高科技医学领域建设一个属于患者的全球化医疗集团”)和使命(“持续创新,为医生提供能挽救并重塑患者生命或改善其生活质量的真善美惠医疗解决方案”)的核心就如同呼吸的空气、太阳的光芒和清晨的雨露一样,让代表全球高科技水平的医疗技术以公平、平等的方式,将健康和长寿带给世界上的每一个角落,每一个社区,每一个家庭和每一位患者。

秉承“致广致大致远致良知,尽精尽微尽心尽力”的管理理念,微创®在强调以人为本的同时,将对细节的追求和创新的坚持深深融入到企业基因之中。“患者和医生是并肩作战的战友,微创®是患者和医生的后勤保障,疾病是我们共同的敌人”,“为患者服务”和“为‘为患者服务的医生’服务”是微创®人共同的信仰。微创®人专注于与患者和医生结成命运共同体,缓解甚至消除各种慢性疾病对生命安全的严重威胁,并在把人类平均健康寿命提升至100岁、120岁甚至150岁的过程中,发挥越来越重要、甚至不可或缺的作用,为满足人类对“健康长寿”永无止境的美好追求做出重要贡献。


Started in 1998, it is a group company integrating the development, manufacturing and marketing of medical devices, focusing on the research and development of cardiovascular intervention products / orthopedic medical devices, etc. it is famous for drug stents and minimally invasive medical devices (Group) Co., Ltd., which was founded in 1998. It is an outstanding innovative medical device group in China, headquartered in Zhangjiang Science City, Shanghai, China No. 1601, Zhangdong Road, Pudong New Area, Shanghai, Suzhou, Jiaxing, Dongguan, Memphis, France, Paris, Milan, Italy, Dominican Republic and other places have established major production (R & D) bases, forming a global R & D, production, marketing and service network. The company has about 5000 employees, from more than 30 countries, of which more than half are Chinese employees. Minimally invasive ® focuses on providing doctors with true, good and beautiful medical solutions that can save and reshape patients' lives or improve their quality of life through continuous innovation. Minimally invasive ® has about 300 products on the market, covering ten business clusters, including cardiovascular intervention and structural heart disease medicine, cardiac rhythm management and electrophysiological medicine, orthopedic implantation and repair, large artery and peripheral vascular intervention, neural intervention and brain science, diabetes and endocrine management, urinary and women's health, surgical operation, medical robot and artificial intelligence. Minimally invasive products have entered more than 8000 hospitals around the world, covering major regions such as Asia Pacific, Europe and the Americas. Globally, on average, every 12 seconds, a minimally invasive ® product is used to treat patients' lives or improve their quality of life or to help them generate new lives. The drug-targeted eluting stent system launched in 2014 makes minimally invasive ® complete the leap from follower and parallel runner to global leader in the field of coronary stent. Minimally invasive ® people's innovation power comes from a brand concept belonging to patients and doctors. The concept and motivation of all business activities come from patients, for patients and for patients; all innovative ideas are taken from doctors, for doctors, and for doctors. "The sun and the moon don't shine, the rain and the dew don't nourish with grass and grass". Micro invasive people firmly believe that everyone has the right to health care, the right to health and the right to live longer, and hope to work together with all sectors of society to actively create a variety of transformative medical means for everyone to enjoy this right. Minimally invasive's vision ("people-oriented, building a global medical group for patients in the field of high-tech medicine represented by micro trauma") and mission ("continuous innovation, providing doctors with true, good and beautiful medical solutions that can save and reshape patients' lives or improve their quality of life") are like breathing air, sun's light and morning dew In the same way, let the medical technology representing the global high-tech level bring health and longevity to every corner, every community, every family and every patient in a fair and equal way. Adhering to the management concept of "broad to the general, far to the conscience, meticulous to the utmost", micro invasive ® emphasizes people-oriented and deeply integrates the pursuit of details and innovation into the corporate gene. "Patients and doctors are comrades in arms, minimally invasive ® is the logistical support for patients and doctors, disease is our common enemy," serve patients "and" serve doctors for patients "are the common beliefs of minimally invasive ® people. Micro invasive people focus on forming a community of common destiny with patients and doctors to alleviate or even eliminate the serious threat of various chronic diseases to life safety, and play an increasingly important, even indispensable role in raising the average healthy life span of human beings to 100, 120 or even 150 years old, so as to make an important contribution to meet the endless pursuit of "healthy and long life" Offer.

本文链接: https://brand.waitui.com/21726326e.html 联系电话:400-8400-501,021-38954600

千城特选小程序码

7×24h 快讯

千红制药:预计2024年归母净利润3.2亿元-3.8亿元,同比增长75.96%-108.95%

36氪获悉,千红制药发布2024年业绩预告。报告显示,预计2024年归母净利润3.2亿元-3.8亿元,同比增长75.96%-108.95%。2024年度销售收入虽因药品价格下降而下降,但主要产品销量均保持增长且毛利率较上年同期持续提升,由此归母净利润实现了同比较大幅度提升。

2小时前

飞荣达:子公司拟3.8亿元收购江苏中煜100%股权

36氪获悉,飞荣达公告,公司全资子公司江苏飞荣达拟收购江苏中煜橡塑科技有限公司(简称“江苏中煜”)100%股权,交易价格为3.8亿元。标的公司是一家以高端橡胶密封件及新能源汽车橡胶制品生产销售为一体的制造型企业,并拥有专业的橡胶材料研发的技术团队。本次收购将丰富公司在新能源领域的产品矩阵,增强公司电磁屏蔽及热管理解决方案的综合能力,有效实现资源整合及业务协同,有利于提升公司综合竞争力及市场份额。

2小时前

中航电测:拟变更证券简称为“中航成飞”

36氪获悉,中航电测公告,公司于2025年1月22日召开2025年第一次临时股东大会,审议通过了《关于变更公司名称、证券简称、经营范围及修订的议案》《关于变更公司证券代码的议案》。公司拟将证券简称由“中航电测”变更为“中航成飞”,英文简称由“ZEMIC”变更为“AVIC CAC”。本次变更后的证券简称及证券代码拟启用日期待定,以深圳证券交易所最终核准的日期为准。公司特别提示广大投资者充分知晓。

2小时前

支付宝:“碰一下钱被隔空盗刷”系摆拍,部分造谣者已被惩处

36氪获悉,据支付宝安全中心微博,近期,部分自媒体为吸引眼球和流量,发布摆拍虚假视频,捏造“使用支付宝碰一下钱被隔空盗刷”等不实内容。经公安机关依法办案,部分造谣者已受到应有的惩处。

2小时前

欧盟据悉提议成立专注于AI等战略技术的高级研究机构

据报道,欧盟将提议仿照美国政府建立一个高级研究项目机构,投资战略技术。欧盟还将呼吁为人工智能建设新的超级计算基础设施。据知情人士和文件消息,这些计划已被纳入欧盟将于1月底发布的新战略草案中,同时发布的还有关于削减监管、改善资金获取、降低能源成本和减轻与关键材料相关的依赖性的建议。(界面)

2小时前

本页详细列出关于Medtronic美敦力的品牌信息,含品牌所属公司介绍,Medtronic美敦力所处行业的品牌地位及优势。
咨询